



dorsaVi signs evaluation agreement with German subsidiary Stryker to assess ViMove2™

Melbourne, Australia, 18 July 2018; dorsaVi (ASX: DVL) today announced it has signed an evaluation agreement with Stryker Leibinger GmbH & Co. KG (Stryker) to evaluate ViMove2™. The project (including payment) is milestone-based and depending on outcomes, may run over a 12-18 month timeframe.

Stryker Leibinger GmbH & Co. KG is the German subsidiary of Stryker Corporation, a Fortune 500 company and one of the world's leading medical technology companies. In February 2018, dorsaVi signed a contract with Stryker Corporation to use dorsaVi's workplace assessment solution, ViSafe™.

dorsaVi Chief Executive Officer Dr Andrew Ronchi said: "ViMove2 is a FDA approved, medical grade wearable technology, and is recognised as a valuable tool in assessing not only injury recovery and prevention, but critical surgical procedures with the ultimate aim of improving patient outcomes in the short and medium term. We are very pleased to be partnering with Stryker in both Germany and the US; one of the most recognisable medical technology companies in the world."

The ViMove2 contract includes a mutual right to terminate with 30 days' prior notice. Any services incurred or committed prior to termination must be paid in full.

– ENDS –

For more information about dorsaVi or to arrange an interview, please contact:

MEDIA

Megan Connell

dorsaVi

0416 116 526

mconnell@dorsavi.com

INVESTOR

Arthur Chan

WE Buchan

0404 369 388

arthurc@we-buchan.com

About dorsaVi

dorsaVi (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in elite sports, occupational health and safety and clinical applications. dorsaVi believes its wearable sensor technology enables – for the first time – many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.

Our technology has applications across three sectors:

- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions - ViMove, ViMove2 and Professional Suite – which provide objective assessment, monitoring outside the clinic and immediate biofeedback. dorsaVi is currently used by medical and physiotherapy practices globally.
- **Elite Sports:** ViPerform is allowing coaches and medical teams managing elite athletes and teams to screen athletes and provide objective evidence for decisions on return to play, measure biomechanics and provide immediate biofeedback out on the field, tailor and track training programs and optimise technique and peak performance. ViPerform is being used in the US by the National Basketball Association (NBA), the Major Soccer League (MLS) and the National Football League (NFL), by the AFL and NRL clubs, Cricket Australia, and the Australian Institute of Sport (AIS) in Australia, and by Barclays Premier League (EPL) clubs, England and Wales Cricket Board and the Board of Control for Cricket in India as well as various Olympic teams and athletes internationally.
- **OHS:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to workplace design, equipment or methods based on objective evidence. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor), Crown and BHP Billiton.

Further information is available at www.dorsavi.com.